{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:31:53Z","timestamp":1791822713597,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>This study aims to evaluate the safety and efficacy of escitalopram and sertraline in post-stroke depression (PSD) patients, to provide more reliable therapeutics for cardiovascular and psychiatric clinical practice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We recruited 60 patients (aged 40\u201389 years old) with an ICD-10 diagnosis of PSD, who were then randomly assigned to two groups and treated with flexible doses of escitalopram (10 to 20 mg\/day, <jats:italic>n<\/jats:italic>\u2009=\u200930) or sertraline (50 to 200 mg\/day, <jats:italic>n<\/jats:italic>\u2009=\u200930) for consecutive 8 weeks, respectively. The 24-item Hamilton Depression Rating Scale (HAMD-24), the 14-item Hamilton Anxiety Rating Scale (HAMA-14), the Treatment Emergent Symptom Scale (TESS), the Montreal Cognitive Assessment Scale (MOCA), and the Activity of Daily Living scale (ADL) were used to assess patients before, during, and after treatment for depression, anxiety, adverse effects, cognitive function, and daily living activities. Repeated measures ANOVA, the Mann\u2013Whitney U test, the chi-square test (\u03c7<jats:sup>2<\/jats:sup>), or Fisher\u2019s exact test was employed to assess baseline demographics, response rate, adverse effects rate, and changes in other clinical variables.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Significant reduction in HAMD-24 and HAMA-14 scores was evaluated at baseline, as well as 1, 3, 4, 6, and 8\u00a0weeks of drug intervention (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). There was a significant group difference in post-treatment HAMD-24 scores (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05), but no difference was observed in HAMA-14 scores (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). Further analysis showed a significant variance in the HAMD-24 scores between the two groups at the end of the first week (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). The incidence of adverse effects in both patient groups was mild, but there was a statistically significant difference between the two groups (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). The improvement in cognitive function and the recovery of daily living abilities were comparable between both groups (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Escitalopram and sertraline showed comparable efficacy for anxiety symptoms, cognitive function, and daily living abilities in PSD patients. In addition, escitalopram was more appropriate for alleviating depressive symptoms. To validate the conclusion, trials with a larger sample size are in demand in the future. The registration number is ChiCTR1800017373.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-024-05833-w","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T07:02:09Z","timestamp":1715756529000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["The safety and efficacy of escitalopram and sertraline in post-stroke depression: a randomized controlled trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Ning","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0570-670X","authenticated-orcid":false,"given":"Shaohua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"key":"5833_CR1","doi-asserted-by":"publisher","first-page":"E52","DOI":"10.5888\/pcd16.180411","volume":"16","author":"X Tong","year":"2019","unstructured":"Tong X, Yang Q, Ritchey MD, et al. The Burden of Cerebrovascular Disease in the United States. Prev Chronic Dis. 2019;16:E52. https:\/\/doi.org\/10.5888\/pcd16.180411.","journal-title":"Prev Chronic Dis"},{"issue":"4","key":"5833_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41569-018-0119-4","volume":"16","author":"D Zhao","year":"2019","unstructured":"Zhao D, Liu J, Wang M, Zhang X, Zhou M. Epidemiology of cardiovascular disease in China: current features and implications. Nat Rev Cardiol. 2019;16(4):203\u201312. https:\/\/doi.org\/10.1038\/s41569-018-0119-4.","journal-title":"Nat Rev Cardiol"},{"key":"5833_CR3","doi-asserted-by":"publisher","first-page":"103252","DOI":"10.1016\/j.ajp.2022.103252","volume":"77","author":"S Li","year":"2022","unstructured":"Li S, Guo B, Yang Q, et al. Evaluation of depression status and its influencing factors in convalescent elderly patients with first-episode stroke. Asian J Psychiatr. 2022;77:103252. https:\/\/doi.org\/10.1016\/j.ajp.2022.103252.","journal-title":"Asian J Psychiatr"},{"issue":"7","key":"5833_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11940-019-0570-5","volume":"21","author":"SE Starkstein","year":"2019","unstructured":"Starkstein SE, Hayhow BD. Treatment of Post-Stroke Depression. Curr Treat Options Neurol. 2019;21(7):31. https:\/\/doi.org\/10.1007\/s11940-019-0570-5.","journal-title":"Curr Treat Options Neurol"},{"issue":"3","key":"5833_CR5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1136\/jnnp-2017-316882","volume":"89","author":"EJ Lee","year":"2018","unstructured":"Lee EJ, Oh MS, Kim JS, et al. Serotonin transporter gene polymorphisms may be associated with poststroke neurological recovery after escitalopram use. J Neurol Neurosurg Psychiatry. 2018;89(3):271\u20136. https:\/\/doi.org\/10.1136\/jnnp-2017-316882.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"5833_CR6","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1016\/j.euroneuro.2015.06.007","volume":"25","author":"R Strawbridge","year":"2015","unstructured":"Strawbridge R, Arnone D, Danese A, Papadopoulos A, Herane Vives A, Cleare AJ. Inflammation and clinical response to treatment in depression: A meta-analysis. Eur Neuropsychopharmacol. 2015;25(10):1532\u201343. https:\/\/doi.org\/10.1016\/j.euroneuro.2015.06.007.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"5833_CR7","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1007\/s00415-021-10597-4","volume":"269","author":"J Guo","year":"2022","unstructured":"Guo J, Wang J, Sun W, Liu X. The advances of post-stroke depression: 2021 update. J Neurol. 2022;269(3):1236\u201349. https:\/\/doi.org\/10.1007\/s00415-021-10597-4.","journal-title":"J Neurol"},{"issue":"6","key":"5833_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2329-6895.1000394","volume":"6","author":"S Sangam","year":"2018","unstructured":"Sangam S. Post-stroke Depression: Epidemiology, Diagnosis, Risk Factors, and Management. Neurological Disorders. 2018;6(6):1\u20135. https:\/\/doi.org\/10.4172\/2329-6895.1000394.","journal-title":"Neurological Disorders"},{"key":"5833_CR9","doi-asserted-by":"publisher","unstructured":"Frank D, Gruenbaum BF, Zlotnik A, Semyonov M, Frenkel A, Boyko M. Pathophysiology and Current Drug Treatments for Post-Stroke Depression: A Review. Int J Mol Sci 2022, 23(23). https:\/\/doi.org\/10.3390\/ijms232315114.","DOI":"10.3390\/ijms232315114"},{"key":"5833_CR10","doi-asserted-by":"publisher","first-page":"734170","DOI":"10.3389\/fneur.2021.734170","volume":"12","author":"I Stuckart","year":"2021","unstructured":"Stuckart I, Siepmann T, Hartmann C, et al. Sertraline for Functional Recovery After Acute Ischemic Stroke: A Prospective Observational Study. Front Neurol. 2021;12:734170. https:\/\/doi.org\/10.3389\/fneur.2021.734170.","journal-title":"Front Neurol"},{"issue":"11","key":"5833_CR11","doi-asserted-by":"publisher","first-page":"e8930","DOI":"10.1590\/1414-431X20208930","volume":"53","author":"JX Cao","year":"2020","unstructured":"Cao JX, Liu L, Sun YT, Zeng QH, Wang Y, Chen JC. Effects of the prophylactic use of escitalopram on the prognosis and the plasma copeptin level in patients with acute cerebral infarction. Braz J Med Biol Res. 2020;53(11):e8930. https:\/\/doi.org\/10.1590\/1414-431X20208930.","journal-title":"Braz J Med Biol Res"},{"issue":"2","key":"5833_CR12","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1161\/STR.0000000000000113","volume":"48","author":"A Towfighi","year":"2017","unstructured":"Towfighi A, Ovbiagele B, El Husseini N, et al. Poststroke Depression: A Scientific Statement for Healthcare Professionals From the American Heart Association\/American Stroke Association. Stroke. 2017;48(2):e30\u201343. https:\/\/doi.org\/10.1161\/STR.0000000000000113.","journal-title":"Stroke"},{"key":"5833_CR13","doi-asserted-by":"publisher","first-page":"106651","DOI":"10.1016\/j.clineuro.2021.106651","volume":"205","author":"XW Yao","year":"2021","unstructured":"Yao XW, Li YL, Yu ZJ, Mo CY, Pan HS, Li CY. The efficacy and safety of agomelatine, sertraline, and escitalopram for senile post-stroke depression: A randomized double-blind placebo-controlled trial. Clin Neurol Neurosurg. 2021;205:106651. https:\/\/doi.org\/10.1016\/j.clineuro.2021.106651.","journal-title":"Clin Neurol Neurosurg"},{"issue":"4","key":"5833_CR14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/YIC.0000000000000023","volume":"29","author":"C Sanchez","year":"2014","unstructured":"Sanchez C, Reines EH, Montgomery SA. A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike? Int Clin Psychopharmacol. 2014;29(4):185\u201396. https:\/\/doi.org\/10.1097\/YIC.0000000000000023.","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"5833_CR15","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1185\/030079906X167273","volume":"23","author":"D Ventura","year":"2007","unstructured":"Ventura D, Armstrong EP, Skrepnek GH, Haim EM. Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. Curr Med Res Opin. 2007;23(2):245\u201350. https:\/\/doi.org\/10.1185\/030079906X167273.","journal-title":"Curr Med Res Opin"},{"issue":"13","key":"5833_CR16","doi-asserted-by":"publisher","first-page":"e025868","DOI":"10.1161\/JAHA.122.025868","volume":"11","author":"HM Kalbouneh","year":"2022","unstructured":"Kalbouneh HM, Toubasi AA, Albustanji FH, Obaid YY, Al-Harasis LM. Safety and Efficacy of SSRIs in Improving Poststroke Recovery: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2022;11(13):e025868. https:\/\/doi.org\/10.1161\/JAHA.122.025868.","journal-title":"J Am Heart Assoc"},{"key":"5833_CR17","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.jad.2020.02.005","volume":"266","author":"X Li","year":"2020","unstructured":"Li X, Zhang C. Comparative efficacy of nine antidepressants in treating Chinese patients with post-stroke depression: A network meta-analysis. J Affect Disord. 2020;266:540\u20138. https:\/\/doi.org\/10.1016\/j.jad.2020.02.005.","journal-title":"J Affect Disord"},{"key":"5833_CR18","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jocn.2020.08.013","volume":"80","author":"Z Yuan","year":"2020","unstructured":"Yuan Z, Chen Z, Xue M, Zhang J, Leng L. Application of antidepressants in depression: A systematic review and meta-analysis. J Clin Neurosci. 2020;80:169\u201381. https:\/\/doi.org\/10.1016\/j.jocn.2020.08.013.","journal-title":"J Clin Neurosci"},{"key":"5833_CR19","doi-asserted-by":"publisher","first-page":"115391","DOI":"10.1016\/j.psychres.2023.115391","volume":"327","author":"X Luo","year":"2023","unstructured":"Luo X, Zhu D, Li J, et al. Selection of the optimal dose of sertraline for depression: A dose-response meta-analysis of randomized controlled trials. Psychiatry Res. 2023;327:115391. https:\/\/doi.org\/10.1016\/j.psychres.2023.115391.","journal-title":"Psychiatry Res"},{"issue":"1","key":"5833_CR20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1517\/17425255.2014.863873","volume":"10","author":"D Pastoor","year":"2014","unstructured":"Pastoor D, Gobburu J. Clinical pharmacology review of escitalopram for the treatment of depression. Expert Opin Drug Metab Toxicol. 2014;10(1):121\u20138. https:\/\/doi.org\/10.1517\/17425255.2014.863873.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"5833_CR21","unstructured":"Landy K, Rosani A, Estevez R. Escitalopram. 2023. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. PMID:32491666. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557734\/."},{"issue":"11","key":"5833_CR22","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1016\/j.euroneuro.2016.09.001","volume":"26","author":"F Matth\u00e4us","year":"2016","unstructured":"Matth\u00e4us F, Haddjeri N, S\u00e1nchez C, et al. The allosteric citalopram binding site differentially interferes with neuronal firing rate and SERT trafficking in serotonergic neurons. Eur Neuropsychopharmacol. 2016;26(11):1806\u201317. https:\/\/doi.org\/10.1016\/j.euroneuro.2016.09.001.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"5833_CR23","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1021\/acschemneuro.1c00694","volume":"13","author":"W Xue","year":"2022","unstructured":"Xue W, Fu T, Deng S, Yang F, Yang J, Zhu F. Molecular Mechanism for the Allosteric Inhibition of the Human Serotonin Transporter by Antidepressant Escitalopram. ACS Chem Neurosci. 2022;13(3):340\u201351. https:\/\/doi.org\/10.1021\/acschemneuro.1c00694.","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"5833_CR24","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1038\/s41598-022-05560-w","volume":"12","author":"RF Feng","year":"2022","unstructured":"Feng RF, Ma R, Wang P, et al. Efficacy of escitalopram for poststroke depression: a systematic review and meta-analysis. Sci Rep. 2022;12(1):3304. https:\/\/doi.org\/10.1038\/s41598-022-05560-w.","journal-title":"Sci Rep"},{"key":"5833_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.pbb.2016.02.005","volume":"144","author":"C Dong","year":"2016","unstructured":"Dong C, Zhang JC, Yao W, et al. Effects of escitalopram, R-citalopram, and reboxetine on serum levels of tumor necrosis factor-\u03b1, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration. Pharmacol Biochem Behav. 2016;144:7\u201312. https:\/\/doi.org\/10.1016\/j.pbb.2016.02.005.","journal-title":"Pharmacol Biochem Behav"},{"key":"5833_CR26","doi-asserted-by":"publisher","first-page":"110762","DOI":"10.1016\/j.pnpbp.2023.110762","volume":"125","author":"HT \u00d6nal","year":"2023","unstructured":"\u00d6nal HT, Yetkin D, Ayaz F. Escitalopram\u2019s inflammatory effect on the mammalian macrophages and its intracellular mechanism of action. Prog Neuropsychopharmacol Biol Psychiatry. 2023;125:110762. https:\/\/doi.org\/10.1016\/j.pnpbp.2023.110762.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"5","key":"5833_CR27","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1038\/s41386-021-01186-0","volume":"47","author":"L Lu","year":"2022","unstructured":"Lu L, Li H, Baumel WT, et al. Acute neurofunctional effects of escitalopram during emotional processing in pediatric anxiety: a double-blind, placebo-controlled trial. Neuropsychopharmacology. 2022;47(5):1081\u20137. https:\/\/doi.org\/10.1038\/s41386-021-01186-0.","journal-title":"Neuropsychopharmacology"},{"key":"5833_CR28","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jad.2023.05.085","volume":"338","author":"TS Shi","year":"2023","unstructured":"Shi TS, Li WY, Chen YM, et al. The antidepressant-like effects of escitalopram in mice require salt-inducible kinase 1 and CREB-regulated transcription co-activator 1 in the paraventricular nucleus of the hypothalamus. J Affect Disord. 2023;338:228\u201338. https:\/\/doi.org\/10.1016\/j.jad.2023.05.085.","journal-title":"J Affect Disord"},{"key":"5833_CR29","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.psyneuen.2015.01.008","volume":"53","author":"PS Ho","year":"2015","unstructured":"Ho PS, Yeh YW, Huang SY, Liang CS. A shift toward T helper 2 responses and an increase in modulators of innate immunity in depressed patients treated with escitalopram. Psychoneuroendocrinology. 2015;53:246\u201355. https:\/\/doi.org\/10.1016\/j.psyneuen.2015.01.008.","journal-title":"Psychoneuroendocrinology"},{"issue":"4","key":"5833_CR30","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/s00415-014-7251-9","volume":"261","author":"D Shin","year":"2014","unstructured":"Shin D, Oh YH, Eom CS, Park SM. Use of selective serotonin reuptake inhibitors and risk of stroke: a systematic review and meta-analysis. J Neurol. 2014;261(4):686\u201395. https:\/\/doi.org\/10.1007\/s00415-014-7251-9.","journal-title":"J Neurol"},{"issue":"11","key":"5833_CR31","doi-asserted-by":"publisher","first-page":"CD009286","DOI":"10.1002\/14651858.CD009286.pub4","volume":"11","author":"LA Legg","year":"2021","unstructured":"Legg LA, Rudberg AS, Hua X, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev. 2021;11(11):CD009286. https:\/\/doi.org\/10.1002\/14651858.CD009286.pub4.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"5833_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaneurol.2020.3142","volume":"78","author":"P Kubiszewski","year":"2020","unstructured":"Kubiszewski P, Sugita L, Kourkoulis C, et al. Association of Selective Serotonin Reuptake Inhibitor Use After Intracerebral Hemorrhage With Hemorrhage Recurrence and Depression Severity. JAMA Neurol. 2020;78(1):1\u20138. https:\/\/doi.org\/10.1001\/jamaneurol.2020.3142.","journal-title":"JAMA Neurol"},{"issue":"9","key":"5833_CR33","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1161\/STROKEAHA.120.032973","volume":"52","author":"JS Jones","year":"2021","unstructured":"Jones JS, Kimata R, Almeida OP, Hankey GJ. Risk of Fractures in Stroke Patients Treated With a Selective Serotonin Reuptake Inhibitor: A Systematic Review and Meta-Analysis. Stroke. 2021;52(9):2802\u20138. https:\/\/doi.org\/10.1161\/STROKEAHA.120.032973.","journal-title":"Stroke"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-024-05833-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-024-05833-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-024-05833-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T07:05:27Z","timestamp":1715756727000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-024-05833-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5833"],"URL":"https:\/\/doi.org\/10.1186\/s12888-024-05833-w","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,15]]},"assertion":[{"value":"3 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The original study submitted for publication has been carried out in accordance with the Declaration of Helsinki. All procedures adhered to the ethical standards set by the responsible committee on human experimentation, both at the institutional and national levels. The double-blind, randomized, and controlled trial received approval from the Ethics Committee of the Affiliated First Hospital of Zhejiang University School of Medicine. The registration number is ChiCTR1800017373. Informed consent forms were obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"365"}}